The Mexico Immunoassay Market was valued at $348.92 Million in 2025 and projected to reach to $439.85 Million by 2030, representing a compound annual growth rate of 4.7%. Mexico's immunoassay market is positioned for steady growth through 2030, driven by expanding healthcare accessibility and modernization of diagnostic infrastructure across the country.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico's immunoassay market is valued at USD 348.92 million in 2025, with projected growth to USD 439.85 million by 2030, representing a steady CAGR of 4.7%.
Increasing investments in Mexico's healthcare infrastructure are driving demand for advanced diagnostic testing capabilities across clinical laboratories, hospitals, and diagnostic centers nationwide.
Rising prevalence of chronic diseases and infectious conditions in Mexico is fueling demand for immunoassay testing in both public and private healthcare settings.
Mexico's immunoassay sector benefits from growing awareness of preventive healthcare, expanding laboratory networks, and increasing adoption of automated diagnostic systems in urban and emerging markets.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides automated immunoassay testing through the Alinity i and ARCHITECT systems for clinical laboratory and blood screening applications. | Improves testing throughput within a compact footprint | Supports broad testing menus | Provides greater walk-away time through automated workflows | Supports consistent and reliable results. |
|
|
Provides automated immunoassay testing through cobas e analyzers using electrochemiluminescence technology across infectious disease, cardiac, endocrine, fertility, and oncology applications. | Provides high sensitivity and reproducibility through ECL technology | Supports high-throughput testing | Enables continuous reagent loading during operation | Supports carryover-free sample processing. |
|
|
Provides immunoassay testing through Atellica IM, ADVIA Centaur, and IMMULITE systems across infectious disease, cardiac, endocrine, and reproductive health testing. | Supports high immunoassay testing throughput | Enables rapid turnaround for key assays | Provides automated QC and remote monitoring | Supports broad assay menus and scalable laboratory configurations. |
|
|
Provides automated immunoassay testing through DxI and Access analyzers for clinical laboratories with varying testing volumes. | Provides high productivity per laboratory footprint | Reduces routine maintenance requirements | Supports remote real-time system monitoring | Enables expanded assay processing and laboratory productivity. |
|
|
Provides Bio-Plex multiplex immunoassays and ELISA-based solutions for biomarker, cytokine, protein, and antibody analysis across research and clinical applications. | Enables simultaneous measurement of multiple analytes | Reduces sample volume requirements | Supports high-throughput biomarker analysis | Provides automated data analysis and reproducible assay performance. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CLIA (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6.1% from 2025 to 2030 |
| Largest Segment | REAGENTS & KITS (Product) |
| Market Size Base Year (Billions) | ~USD 35.48 (2025) |
| Revenue Forecast (Billions) | ~USD 47.7 (2030) |
| Segments Covered | Product, Type, Purchase Mode, Technology, Specimen, Application |
6 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| BLOOD BANKS | 10.64 | 10.62 | 10.69 | 10.9 | 11.61 | 12.13 | 12.79 | 3.7 |
| CLINICAL LABORATORIES | 113.38 | 114.35 | 116.45 | 119.97 | 130.66 | 138.09 | 147.18 | 4.8 |
| HOME CARE SETTINGS | 14.16 | 14.19 | 14.37 | 14.72 | 15.83 | 16.64 | 17.62 | 4.2 |
| HOSPITALS & CLINICS | 267.11 | 268.78 | 273.1 | 280.71 | 304.31 | 320.89 | 341.22 | 4.6 |
| TOTAL | 405.29 | 407.94 | 414.61 | 426.3 | 462.41 | 487.75 | 518.81 | 4.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (oral, sterile, packaging, lifecycle),Pharmaceutical Development Services (preclinical to clinical),Drug Substance Services (small-molecule and biologics APIs), |
| ALERE INC | United States | Private Company | Infectious disease diagnostics (rapid and serology, including ELISA and automated systems),Cardiometabolic and critical care point-of-care (blood gas, lipids, glucose, D-dimer, troponin, diabetes),Toxicology and workplace drug testing (devices, reagents, lab services, alcohol tests), |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining and metals, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, nuclear security, logistics, mission-critical O&M), |
| CEPHEID INC. | United States | Private Company | Infectious disease & healthcare-associated infection assays (Xpert on GeneXpert),Virology assays (including emergency use authorization tests),Oncology and genetics assays, |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents, including NEO, Echo, Capture),Transplant & Molecular (HLA, HPA assays, Array Imaging System, BASIS, platelet-focused products),Other / Services and Ancillary Products, |
| UNILABS | Switzerland | Private Company | Routine & Specialty Laboratory Testing,Medical Imaging,Pathology & Centres of Excellence (IVF, Fertility, Pregnancy, Targeted Diagnostics), |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and food/environmental microbiology,Urinalysis test strips and analyzers, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| DANAHER | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (analytical instruments, genomics, and lab automation),Diagnostics (clinical instruments and consumables), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| REVVITY | United States | Public Company | Diagnostics instruments and systems,Diagnostics reagents, assays, and consumables,Life science reagents and genomic workflow tools, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology, Metabolic Disorders, Tumor Markers, Oncology,Molecular Diagnostics – Simplexa and Congenital CMV, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Tools,Other / Informatics & Software, |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| BIOMÉRIEUX | France | Public Company | Clinical microbiology & AST (VITEK, CHROMID, ETEST, culture media, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays & biomarkers (VIDAS, Hybiome CLIA), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions), |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers & reagents,Coagulation diagnostics,Urinalysis, blood gas, electrolyte, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. | China | Public Company | Patient monitoring and life support (monitoring, ventilators, defibrillation, AED, anesthesia),Ultrasound and medical imaging (ultrasound, radiology, endoscope camera system),In-vitro diagnostics (CLIA, chemistry, hematology, laboratory diagnostics), |
Patheon Inc. is a Netherlands-based pharmaceutical manufacturing company with 9,100 employees. Operating as a private company, it provides contract development and manufacturing services to the pharmaceutical industry.
Alere Inc. is a United States-based diagnostics company founded in 1981 with 9,700 employees. Operating as a private company, it specializes in rapid diagnostic testing solutions for healthcare markets.
Fluor Corporation is a United States-based engineering and construction company founded in 1912 with 22,995 employees. As a public company, it provides design, engineering, procurement, and construction services across multiple industries.
Cepheid Inc. is a United States-based molecular diagnostics company founded in 1996 with 1,700 employees. Operating as a private company, it develops and manufactures automated molecular testing systems.
Immucor, Inc. is a United States-based immunohematology company founded in 1982 with 1,125 employees. As a private company, it specializes in blood bank and transfusion medicine diagnostic solutions.
Unilabs is a Switzerland-based clinical laboratory services company founded in 1987 with 1,897 employees. As a private company, it operates diagnostic laboratories across multiple European countries.
Eiken Chemical Co., Ltd. is a Japan-based diagnostics and pharmaceutical company founded in 1939 with 696 employees. As a public company, it manufactures in vitro diagnostic reagents and pharmaceutical products.
Abbott is a United States-based healthcare company founded in 1888 with 115,000 employees. As a public company, it develops and manufactures diagnostics, medical devices, pharmaceuticals, and nutritional products.
Siemens Healthineers AG is a Germany-based medical technology company founded in 1896 with 72,369 employees. As a public company, it manufactures and distributes diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.
Danaher is a United States-based conglomerate founded in 1969 with 59,000 employees. As a public company, it operates across multiple sectors including life sciences, diagnostics, and environmental solutions.
Thermo Fisher Scientific Inc. is a United States-based life sciences company founded in 1956 with 125,000 employees. As a public company, it provides laboratory equipment, reagents, and analytical instruments globally.
Revvity is a United States-based life sciences and diagnostics company founded in 1937 with 11,000 employees. As a public company, it manufactures and distributes analytical instruments and reagents for research and diagnostics.
DiaSorin S.p.A. is an Italy-based diagnostics company founded in 1968 with 3,242 employees. As a public company, it develops and manufactures in vitro diagnostic products for clinical laboratories.
Bio-Rad Laboratories, Inc. is a United States-based life sciences company founded in 1952 with 7,450 employees. As a public company, it manufactures and distributes reagents, instruments, and quality control products for clinical and research laboratories.
QuidelOrtho Corporation is a United States-based diagnostics company founded in 1979 with 6,500 employees. As a public company, it develops and manufactures rapid diagnostic tests and laboratory instruments.
bioMérieux is a France-based diagnostics company founded in 1963 with 14,894 employees. As a public company, it specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and clinical diagnostics.
QIAGEN is a Netherlands-based molecular diagnostics company founded in 1984 with 5,500 employees. As a public company, it develops and manufactures sample preparation and molecular testing solutions.
Sysmex Corporation is a Japan-based diagnostics company founded in 1968 with 10,861 employees. As a public company, it manufactures and distributes hematology, hemostasis, and clinical chemistry analyzers.
Agilent Technologies, Inc. is a United States-based life sciences and diagnostics company founded in 1999 with 18,000 employees. As a public company, it provides analytical instruments, software, and services for research and diagnostics.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a China-based medical device company founded in 1991 with 21,288 employees. As a public company, it manufactures and distributes diagnostic imaging, patient monitoring, and laboratory instruments globally.
Mexico's immunoassay market is valued at USD 348.92 million in 2025.
Mexico's immunoassay market is forecast to reach USD 439.85 million by 2030.
Mexico's immunoassay market is expected to grow at a CAGR of 4.7% from 2025 to 2030.
Key drivers include healthcare infrastructure modernization, rising chronic disease prevalence, expanding middle-class populations, technological advancements in diagnostic platforms, and increased laboratory automation adoption across Mexico.
Mexico serves as a regional healthcare hub in Latin America, attracting both domestic and international manufacturers and supporting broader market expansion across the region.
This study analyzes key market dynamics, including drivers, opportunities, restraints, and challenges, as well as major players’ strategies. It also monitors developments among leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study examines the immunoassay market’s competitive landscape by evaluating market participants against criteria within the overarching categories of business and product strategy. To estimate market size, the study employed both top-down and bottom-up approaches. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
The four steps involved in estimating the market size are as follows:
In the secondary research process, various secondary sources such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold- and silver-standard websites; regulatory bodies; and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
In the primary research process, we interviewed various sources from the supply and demand sides to obtain qualitative and quantitative information for this report. Primary sources were industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations across all segments of this industry’s value chain. We conducted in-depth interviews with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:

Note 1: C-level executives include Chief Executive Officers (CEOs), Chief Financial Officers (CFOs), Chief Operating Officers (COOs), and Vice Presidents (VPs).
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue as of 2025. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
For global market value, we calculated annual revenue figures using revenue mapping for major product manufacturers and OEMs active in the global immunoassay market. We identified all major product manufacturers at the global and/or country/regional level. We mapped revenue for the respective business segments/subsegments of the major players. Additionally, the global market was split into various segments and subsegments:
The data above was consolidated, supplemented with detailed inputs and analysis from MarketsandMarkets, and presented in this report.

After determining the overall market size using the market size estimation processes, we split the market into several segments and subsegments. To complete the overall market engineering process and arrive at precise statistics for each market segment and subsegment, we used data triangulation and market breakdown procedures, where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides of the immunoassay industry.
An immunoassay is a biochemistry-based test that quantifies the presence or concentration of an analyte. An analyte can be a large protein or antibody produced due to an infection. Immunoassays have become popular and well-established procedures in laboratories. They provide quick, accurate, and precise results. This technique is mostly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.
Based on the market data provided, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
Further breakdown of the Rest of Europe immunoassay market into Switzerland, Denmark, Austria, and others
Further breakdown of the Rest of Asia Pacific immunoassay market into Hong Kong, Taiwan, and others
Further breakdown of the Rest of Latin America immunoassay market into Argentina, Colombia, Chile, Ecuador, and others
Further breakdown of the Southeast Asian immunoassay market into Malaysia, Singapore, Australia, New Zealand, and others
Market Share Analysis, by region (North America and Europe), which provides the details about the share of the top 3 to 5 key players in the immunoassay market
Competitive leadership mapping for established players in the US
Full forecast, segment splits, and company analysis for all Immunoassay Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report